Capsule endoscopy is part of the diagnostic approach to patients with suspected small bowel bleeding and data on its clinical impact are still limited in developing countries. The primary aim of the present study was to determine its impact on subsequent diagnostic and therapeutic decisions.
Material and methods
A retrospective study was conducted that included all the patients that underwent capsule endoscopy with the PillCam™ SB 3 Capsule system due to suspected small bowel bleeding treated at the Hospital Universitario Fundación Valle del Lili between January 2011 and December 2020.
Results
A total of 158 patients met the inclusion criteria. Mean patient age was 63 years (interquartile range [IQR], 52-74), 53.6% of the patients were women, and high blood pressure was the most frequent comorbidity (43.7%). The main indication was overt bleeding (58.2%). Of all the capsule endoscopies carried out, 63.9% showed lesions that were potentially responsible for bleeding. Medical or surgical treatment was indicated in 63.3% of the case total. Rebleeding at 6 months occurred in 15 patients and there were 2 deaths due to gastrointestinal bleeding at 6 months.
Conclusions
Capsule endoscopy has a high impact on patients with suspected small bowel bleeding, with respect to clinical decision-making, as well as rebleeding, hospitalization, and mortality outcomes. The positivity rate of lesions potentially responsible for bleeding was similar to that reported in developed countries.
{"title":"Clinical impact of capsule endoscopy on patients with suspected small bowel bleeding: Experience at a highly specialized hospital in Colombia","authors":"C.J. Vargas-Potes , I.L. Zapata-Vásquez , N.E. Rojas-Rojas , C.A. Rojas-Rodríguez","doi":"10.1016/j.rgmxen.2023.04.014","DOIUrl":"10.1016/j.rgmxen.2023.04.014","url":null,"abstract":"<div><h3>Introduction and aims</h3><p>Capsule endoscopy is part of the diagnostic approach to patients with suspected small bowel bleeding and data on its clinical impact are still limited in developing countries. The primary aim of the present study was to determine its impact on subsequent diagnostic and therapeutic decisions.</p></div><div><h3>Material and methods</h3><p>A retrospective study was conducted that included all the patients that underwent capsule endoscopy with the PillCam™ SB 3 Capsule system due to suspected small bowel bleeding treated at the Hospital Universitario Fundación Valle del Lili between January 2011 and December 2020.</p></div><div><h3>Results</h3><p>A total of 158 patients met the inclusion criteria. Mean patient age was 63 years (interquartile range [IQR], 52-74), 53.6% of the patients were women, and high blood pressure was the most frequent comorbidity (43.7%). The main indication was overt bleeding (58.2%). Of all the capsule endoscopies carried out, 63.9% showed lesions that were potentially responsible for bleeding. Medical or surgical treatment was indicated in 63.3% of the case total. Rebleeding at 6 months occurred in 15 patients and there were 2 deaths due to gastrointestinal bleeding at 6 months.</p></div><div><h3>Conclusions</h3><p>Capsule endoscopy has a high impact on patients with suspected small bowel bleeding, with respect to clinical decision-making, as well as rebleeding, hospitalization, and mortality outcomes. The positivity rate of lesions potentially responsible for bleeding was similar to that reported in developed countries.</p></div>","PeriodicalId":74705,"journal":{"name":"Revista de gastroenterologia de Mexico (English)","volume":"89 2","pages":"Pages 222-231"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2255534X23000993/pdfft?md5=0548eeebc134466dcbfdec7e93b6ba35&pid=1-s2.0-S2255534X23000993-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41222981","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-04-01DOI: 10.1016/j.rgmxen.2023.08.001
D.E. Benavides-Salgado, R.A. Jiménez-Castillo, J.E. Cuéllar-Monterrubio, J.O. Jáquez-Quintana, A. Garza-Galindo, C. Cortes-Hernández, H.J. Maldonado-Garza, D. García-Compeán, J.A. González-González
Introduction and aim
Endoscopic retrograde cholangiopancreatography (ERCP) is a complex procedure. Clinical guidelines assess competence in ERCP through a defined number of procedures, but multiple factors are involved. Our aim was to analyze the morphology of the papilla of Vater as an independent factor in selective common bile duct cannulation during resident training.
Material and methods
Patients that underwent ERCP were studied consecutively. All ERCPs were begun by a resident in training. The type of papilla was classified according to Haraldsson, including those with previous sphincterotomy. Cannulation difficulty and success and their relation to the type of papilla were documented. The analysis was divided into three 4-month periods.
Results
Of the 429 patients, cannulation was difficult in 101 (23.5%). The residents achieved selective cannulation of the common bile duct in 276 (64.3%) and the cannulation success rate at the end of their training was 81.7%. Cannulation was performed with the least difficulty in papillae with previous sphincterotomy (2.8%), unlike the type 4 papilla, which was difficult to cannulate in 50% of the cases. The lowest overall cannulation success was in the type 2 papilla (81.8%).
Conclusion
Papilla type can influence cannulation success, but it is not the only related factor. Patients that underwent previous sphincterotomy appear to be the cases in whom ERCP training can be started.
{"title":"Papilla of Vater morphology as an influencing factor in successful cannulation during resident training in advanced endoscopy. A prospective clinical study","authors":"D.E. Benavides-Salgado, R.A. Jiménez-Castillo, J.E. Cuéllar-Monterrubio, J.O. Jáquez-Quintana, A. Garza-Galindo, C. Cortes-Hernández, H.J. Maldonado-Garza, D. García-Compeán, J.A. González-González","doi":"10.1016/j.rgmxen.2023.08.001","DOIUrl":"10.1016/j.rgmxen.2023.08.001","url":null,"abstract":"<div><h3>Introduction and aim</h3><p>Endoscopic retrograde cholangiopancreatography (ERCP) is a complex procedure. Clinical guidelines assess competence in ERCP through a defined number of procedures, but multiple factors are involved. Our aim was to analyze the morphology of the papilla of Vater as an independent factor in selective common bile duct cannulation during resident training.</p></div><div><h3>Material and methods</h3><p>Patients that underwent ERCP were studied consecutively. All ERCPs were begun by a resident in training. The type of papilla was classified according to Haraldsson, including those with previous sphincterotomy. Cannulation difficulty and success and their relation to the type of papilla were documented. The analysis was divided into three 4-month periods.</p></div><div><h3>Results</h3><p>Of the 429 patients, cannulation was difficult in 101 (23.5%). The residents achieved selective cannulation of the common bile duct in 276 (64.3%) and the cannulation success rate at the end of their training was 81.7%. Cannulation was performed with the least difficulty in papillae with previous sphincterotomy (2.8%), unlike the type 4 papilla, which was difficult to cannulate in 50% of the cases. The lowest overall cannulation success was in the type 2 papilla (81.8%).</p></div><div><h3>Conclusion</h3><p>Papilla type can influence cannulation success, but it is not the only related factor. Patients that underwent previous sphincterotomy appear to be the cases in whom ERCP training can be started.</p></div>","PeriodicalId":74705,"journal":{"name":"Revista de gastroenterologia de Mexico (English)","volume":"89 2","pages":"Pages 237-242"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2255534X23000889/pdfft?md5=d5667b608a31f9ecb654c4688f3b8406&pid=1-s2.0-S2255534X23000889-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10188739","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-04-01DOI: 10.1016/j.rgmxen.2023.06.002
A. Fernández-Ramírez , A. Olivas-Martinez , J. Ruiz-Manriquez , E. Kauffman-Ortega , C. Moctezuma-Velázquez , E. Marquez-Guillen , A.G. Contreras , M. Vilatobá , E. González-Flores , R. Cruz-Martínez , N.C. Flores-García , I. García-Juárez
Introduction and aims
Posttransplantation diabetes mellitus (PTDM) is a serious long-term complication that has a negative impact on graft and patient survival. The purpose of the present study was to describe the incidence of PTDM in a Mexican cohort and evaluate its association with a previous family history of diabetes (FHD).
Methods
A retrospective single-center cohort study was conducted on patients undergoing liver transplantation (LT). The primary outcome was time from LT to PTDM. The diagnosis of PTDM was established using the ADA criteria. A mediation analysis that used adjusted Cox regression models and considered pretransplant prediabetes a mediator was performed, to determine the total effect and direct effect of FHD on PTDM.
Results
A total of 152 patients were included, with a median follow-up time of 41 months; 19.2% (n = 29) had pretransplant diabetes. During the follow-up time, 15% of patients developed PTDM (n = 23), with an incidence rate of 4.71 cases/100 person-years. PTDM was significantly higher in patients with FHD, compared with those with no FHD (8.72 cases/100 person-years vs 2.04 cases/100 person-years, respectively; p = 0.001). The adjusted hazard ratio of PTDM for FHD was 4.14 (95% CI 1.60–10.7), p = 0.005) and 3.48 (95% CI 1.35–9.01, p = 0.010), when further controlled for pretransplant prediabetes.
Conclusion
The occurrence of PTDM was similar to that reported in most international studies. As with type 2 diabetes, family history plays an important role in the development of PTDM, even after accounting for pretransplant prediabetes. Patients with FHD should undergo a stricter metabolic program.
{"title":"Posttransplantation diabetes mellitus after liver transplant and the impact of family history of diabetes in a Mexican cohort","authors":"A. Fernández-Ramírez , A. Olivas-Martinez , J. Ruiz-Manriquez , E. Kauffman-Ortega , C. Moctezuma-Velázquez , E. Marquez-Guillen , A.G. Contreras , M. Vilatobá , E. González-Flores , R. Cruz-Martínez , N.C. Flores-García , I. García-Juárez","doi":"10.1016/j.rgmxen.2023.06.002","DOIUrl":"10.1016/j.rgmxen.2023.06.002","url":null,"abstract":"<div><h3>Introduction and aims</h3><p>Posttransplantation diabetes mellitus (PTDM) is a serious long-term complication that has a negative impact on graft and patient survival. The purpose of the present study was to describe the incidence of PTDM in a Mexican cohort and evaluate its association with a previous family history of diabetes (FHD).</p></div><div><h3>Methods</h3><p>A retrospective single-center cohort study was conducted on patients undergoing liver transplantation (LT). The primary outcome was time from LT to PTDM. The diagnosis of PTDM was established using the ADA criteria. A mediation analysis that used adjusted Cox regression models and considered pretransplant prediabetes a mediator was performed, to determine the total effect and direct effect of FHD on PTDM.</p></div><div><h3>Results</h3><p>A total of 152 patients were included, with a median follow-up time of 41 months; 19.2% (<em>n</em> = 29) had pretransplant diabetes. During the follow-up time, 15% of patients developed PTDM (<em>n</em> = 23), with an incidence rate of 4.71 cases/100 person-years. PTDM was significantly higher in patients with FHD, compared with those with no FHD (8.72 cases/100 person-years <em>vs</em> 2.04 cases/100 person-years, respectively; <em>p</em> = 0.001). The adjusted hazard ratio of PTDM for FHD was 4.14 (95% CI 1.60–10.7), <em>p</em> = 0.005) and 3.48 (95% CI 1.35–9.01, <em>p</em> = 0.010), when further controlled for pretransplant prediabetes.</p></div><div><h3>Conclusion</h3><p>The occurrence of PTDM was similar to that reported in most international studies. As with type 2 diabetes, family history plays an important role in the development of PTDM, even after accounting for pretransplant prediabetes. Patients with FHD should undergo a stricter metabolic program.</p></div>","PeriodicalId":74705,"journal":{"name":"Revista de gastroenterologia de Mexico (English)","volume":"89 2","pages":"Pages 249-257"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2255534X23001123/pdfft?md5=356adefe7b0887fcfee1e70c081dbc75&pid=1-s2.0-S2255534X23001123-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49686037","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-04-01DOI: 10.1016/j.rgmxen.2023.05.001
D.G. Fernández-Ávila , V. Dávila-Ruales
Introduction and aims
Inflammatory bowel disease (IBD) has a high economic burden due to its chronicity. Treatment has evolved, thanks to the understanding of IBD pathogenesis and the advent of biologic therapy, albeit the latter increases direct costs. The aim of the present study was to calculate the total cost and cost per patient/year of biologic therapy for IBD and IBD-associated arthropathy in Colombia.
Methods
A descriptive study was conducted. The data were obtained from the Comprehensive Social Protection Information System of the Department of Health for the year 2019, utilizing the medical diagnosis codes of the International Classification of Diseases related to IBD and IBD-associated arthropathy as keywords.
Results
The prevalence of IBD and IBD-associated arthropathy was 61 cases per 100,000 inhabitants, with a female-to-male ratio of 1.5:1. Joint involvement was 3%, and 6.3% of the persons with IBD and IBD-associated arthropathy received biologic therapy. Adalimumab was the most widely prescribed biologic drug (49.2%). Biologic therapy had a cost of $15,926,302 USD and the mean cost per patient/year was $18,428 USD. Adalimumab had the highest impact on healthcare resource utilization, with a total cost of $7,672,320 USD. According to subtype, ulcerative colitis had the highest cost ($10,932,489 USD).
Conclusion
Biologic therapy is expensive, but its annual cost in Colombia is lower than that of other countries due to the government’s regulation of high-cost medications.
{"title":"Frequency of use and cost of biologic treatment for inflammatory bowel disease and inflammatory bowel disease-associated arthropathy in Colombia in 2019","authors":"D.G. Fernández-Ávila , V. Dávila-Ruales","doi":"10.1016/j.rgmxen.2023.05.001","DOIUrl":"10.1016/j.rgmxen.2023.05.001","url":null,"abstract":"<div><h3>Introduction and aims</h3><p>Inflammatory bowel disease (IBD) has a high economic burden due to its chronicity. Treatment has evolved, thanks to the understanding of IBD pathogenesis and the advent of biologic therapy, albeit the latter increases direct costs. The aim of the present study was to calculate the total cost and cost per patient/year of biologic therapy for IBD and IBD-associated arthropathy in Colombia.</p></div><div><h3>Methods</h3><p>A descriptive study was conducted. The data were obtained from the Comprehensive Social Protection Information System of the Department of Health for the year 2019, utilizing the medical diagnosis codes of the International Classification of Diseases related to IBD and IBD-associated arthropathy as keywords.</p></div><div><h3>Results</h3><p>The prevalence of IBD and IBD-associated arthropathy was 61 cases per 100,000 inhabitants, with a female-to-male ratio of 1.5:1. Joint involvement was 3%, and 6.3% of the persons with IBD and IBD-associated arthropathy received biologic therapy. Adalimumab was the most widely prescribed biologic drug (49.2%). Biologic therapy had a cost of $15,926,302 USD and the mean cost per patient/year was $18,428 USD. Adalimumab had the highest impact on healthcare resource utilization, with a total cost of $7,672,320 USD. According to subtype, ulcerative colitis had the highest cost ($10,932,489 USD).</p></div><div><h3>Conclusion</h3><p>Biologic therapy is expensive, but its annual cost in Colombia is lower than that of other countries due to the government’s regulation of high-cost medications.</p></div>","PeriodicalId":74705,"journal":{"name":"Revista de gastroenterologia de Mexico (English)","volume":"89 2","pages":"Pages 213-221"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2255534X23000579/pdfft?md5=0bf3517d27c8a9fa16f2d4e231734f63&pid=1-s2.0-S2255534X23000579-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9489981","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-04-01DOI: 10.1016/j.rgmxen.2023.05.011
C. Durán-Rosas , J. Lara-Carmona , K. Hernández-Flores , F.J. Cabrera-Jorge , F. Roesch-Dietlen , M. Amieva-Balmori , H. Vivanco-Cid , S. Santiesteban-González , P. Thomas-Dupont , J.M. Remes-Troche
Introduction and aims
Celiac disease (CD) is an autoimmune enteropathy that develops in genetically susceptible individuals. The typical gastrointestinal manifestation is diarrhea but symptoms of dyspepsia, such as epigastric pain, nausea, or satiety, can sometimes appear. Previous studies have reported that the prevalence of CD in patients with dyspepsia can be as high as 7%. The aim of the present study was to evaluate CD seroprevalence in subjects with dyspeptic symptoms and a control group in a Mexican population.
Material and methods
A case-control study was conducted on blood donors that answered the PAGI-SYM questionnaire for dyspepsia and in whom IgA antibodies to tissue transglutaminase 2 (IgA anti-tTG2) and IgG antibodies to deamidated gliadin peptide (IgG anti-DGP) were determined. CD seroprevalence in subjects with dyspeptic symptoms and in asymptomatic subjects was compared.
Results
A total of 427 subjects (76.3% men), with a mean patient age of 34 years (range of 18–65 years) were included. Of those participants, 87 (20.3%) had symptoms of dyspepsia (group A) and 340 (79.6%) were asymptomatic (group B). Antibodies were positive in one (1.15%) of the group A subjects (1/87, 95% CI 0.2–6 %), whereas they were positive in 4 (1.18%) of the group B subjects (4/340, 95% CI 0.4–2.9%, p = 0.59).
Conclusions
CD seroprevalence in the study population with dyspeptic symptoms (1%) was not different from that of the control population. Thus, CD screening in Mexican patients with dyspepsia is not justified.
{"title":"Celiac disease seroprevalence in subjects with dyspeptic symptoms. A study on a Mexican population","authors":"C. Durán-Rosas , J. Lara-Carmona , K. Hernández-Flores , F.J. Cabrera-Jorge , F. Roesch-Dietlen , M. Amieva-Balmori , H. Vivanco-Cid , S. Santiesteban-González , P. Thomas-Dupont , J.M. Remes-Troche","doi":"10.1016/j.rgmxen.2023.05.011","DOIUrl":"10.1016/j.rgmxen.2023.05.011","url":null,"abstract":"<div><h3>Introduction and aims</h3><p>Celiac disease (CD) is an autoimmune enteropathy that develops in genetically susceptible individuals. The typical gastrointestinal manifestation is diarrhea but symptoms of dyspepsia, such as epigastric pain, nausea, or satiety, can sometimes appear. Previous studies have reported that the prevalence of CD in patients with dyspepsia can be as high as 7%. The aim of the present study was to evaluate CD seroprevalence in subjects with dyspeptic symptoms and a control group in a Mexican population.</p></div><div><h3>Material and methods</h3><p>A case-control study was conducted on blood donors that answered the PAGI-SYM questionnaire for dyspepsia and in whom IgA antibodies to tissue transglutaminase 2 (IgA anti-tTG2) and IgG antibodies to deamidated gliadin peptide (IgG anti-DGP) were determined. CD seroprevalence in subjects with dyspeptic symptoms and in asymptomatic subjects was compared.</p></div><div><h3>Results</h3><p>A total of 427 subjects (76.3% men), with a mean patient age of 34 years (range of 18–65 years) were included. Of those participants, 87 (20.3%) had symptoms of dyspepsia (group A) and 340 (79.6%) were asymptomatic (group B). Antibodies were positive in one (1.15%) of the group A subjects (1/87, 95% CI 0.2–6 %), whereas they were positive in 4 (1.18%) of the group B subjects (4/340, 95% CI 0.4–2.9%, <em>p</em> = 0.59).</p></div><div><h3>Conclusions</h3><p>CD seroprevalence in the study population with dyspeptic symptoms (1%) was not different from that of the control population. Thus, CD screening in Mexican patients with dyspepsia is not justified.</p></div>","PeriodicalId":74705,"journal":{"name":"Revista de gastroenterologia de Mexico (English)","volume":"89 2","pages":"Pages 243-248"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2255534X23001019/pdfft?md5=b03eef29d2fb7ed03e6435e9f18696e4&pid=1-s2.0-S2255534X23001019-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41222980","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-04-01DOI: 10.1016/j.rgmxen.2024.01.003
Z. Berger, F. Orellana, F. Torres, D. Simián, G. Araneda, P. Toledo
{"title":"Response to Saavedra JA, Seguil YS: Is pancreatic steatosis a common finding in the Chilean population?","authors":"Z. Berger, F. Orellana, F. Torres, D. Simián, G. Araneda, P. Toledo","doi":"10.1016/j.rgmxen.2024.01.003","DOIUrl":"10.1016/j.rgmxen.2024.01.003","url":null,"abstract":"","PeriodicalId":74705,"journal":{"name":"Revista de gastroenterologia de Mexico (English)","volume":"89 2","pages":"Page 317"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2255534X24000355/pdfft?md5=664981de2ef4aca684974a27d88b7b36&pid=1-s2.0-S2255534X24000355-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140870529","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-04-01DOI: 10.1016/j.rgmxen.2023.04.009
J. Contreras-Mancilla , J.P. Cerapio , E. Ruiz , R. Fernández , S. Casavilca-Zambrano , C. Machicado , J.J. Fournié , P. Pineau , S. Bertani
Introduction and aim
Hepatocellular carcinoma (HCC) is the third most frequent cancer of digestive tract tumors in Peru, with a high mortality rate of 17.7 per 100,000 inhabitants. A significant number of HCC cases in Peru do not follow the classic clinical epidemiology of the disease described in other parts of the world. Those patients present with a distinct transcriptome profile and a singular tumor process, suggesting a particular type of hepatocarcinogenesis in a portion of the Peruvian population. Our aim was to understand the clinical and biologic involvement of the epigenetic profile (methylation) and gene expression (transcriptome) of HCC in Peruvian patients.
Methods
HCC and liver transcriptome and DNA methylation profiles were evaluated in 74 Peruvian patients.
Results
When grouped by age, there was greater DNA methylation in younger patients with HCC but no differences with respect to the transcriptomic profile. A high prevalence of the hepatitis B virus (HBV) (>90%) was also observed in the younger patients with HCC. Enrichment analyses in both molecular profiles pinpointed PRC2 as an important molecular effector of that liver tumor process in Peruvian patients.
Conclusion
HCC in Peruvian patients has a unique molecular profile, associated with the presence of HBV, as well as overall DNA hypermethylation related to undifferentiated liver cells or cellular reprogramming.
{"title":"Hepatocellular carcinoma in Peru: A molecular description of an unconventional clinical presentation","authors":"J. Contreras-Mancilla , J.P. Cerapio , E. Ruiz , R. Fernández , S. Casavilca-Zambrano , C. Machicado , J.J. Fournié , P. Pineau , S. Bertani","doi":"10.1016/j.rgmxen.2023.04.009","DOIUrl":"10.1016/j.rgmxen.2023.04.009","url":null,"abstract":"<div><h3>Introduction and aim</h3><p>Hepatocellular carcinoma (HCC) is the third most frequent cancer of digestive tract tumors in Peru, with a high mortality rate of 17.7 per 100,000 inhabitants. A significant number of HCC cases in Peru do not follow the classic clinical epidemiology of the disease described in other parts of the world. Those patients present with a distinct transcriptome profile and a singular tumor process, suggesting a particular type of hepatocarcinogenesis in a portion of the Peruvian population. Our aim was to understand the clinical and biologic involvement of the epigenetic profile (methylation) and gene expression (transcriptome) of HCC in Peruvian patients.</p></div><div><h3>Methods</h3><p>HCC and liver transcriptome and DNA methylation profiles were evaluated in 74 Peruvian patients.</p></div><div><h3>Results</h3><p>When grouped by age, there was greater DNA methylation in younger patients with HCC but no differences with respect to the transcriptomic profile. A high prevalence of the hepatitis B virus (HBV) (>90%) was also observed in the younger patients with HCC. Enrichment analyses in both molecular profiles pinpointed PRC2 as an important molecular effector of that liver tumor process in Peruvian patients.</p></div><div><h3>Conclusion</h3><p>HCC in Peruvian patients has a unique molecular profile, associated with the presence of HBV, as well as overall DNA hypermethylation related to undifferentiated liver cells or cellular reprogramming.</p></div>","PeriodicalId":74705,"journal":{"name":"Revista de gastroenterologia de Mexico (English)","volume":"89 2","pages":"Pages 194-204"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2255534X23000440/pdfft?md5=a7c1bb8f2be40c2803edde67e44834bc&pid=1-s2.0-S2255534X23000440-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9442950","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-04-01DOI: 10.1016/j.rgmxen.2024.02.002
G.E. Castro-Narro , M.E. Rinella
{"title":"The new hepatic steatosis nomenclature. No more NAFLD!","authors":"G.E. Castro-Narro , M.E. Rinella","doi":"10.1016/j.rgmxen.2024.02.002","DOIUrl":"10.1016/j.rgmxen.2024.02.002","url":null,"abstract":"","PeriodicalId":74705,"journal":{"name":"Revista de gastroenterologia de Mexico (English)","volume":"89 2","pages":"Pages 312-313"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2255534X24000380/pdfft?md5=c3404b1c7509336db31136b6f42a4d9f&pid=1-s2.0-S2255534X24000380-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141094777","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-04-01DOI: 10.1016/j.rgmxen.2024.01.002
J. Saavedra, Y. Seguil
{"title":"Is pancreatic steatosis a common finding in the Chilean population?","authors":"J. Saavedra, Y. Seguil","doi":"10.1016/j.rgmxen.2024.01.002","DOIUrl":"10.1016/j.rgmxen.2024.01.002","url":null,"abstract":"","PeriodicalId":74705,"journal":{"name":"Revista de gastroenterologia de Mexico (English)","volume":"89 2","pages":"Page 316"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2255534X24000343/pdfft?md5=1d3e46d7f50d0ff5a8ea70bc36c5bf6f&pid=1-s2.0-S2255534X24000343-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140862235","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号